Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo- and Active-controlled, 3-way Crossover, Phase 1 Study to Evaluate the Effect of EVP-6124 at Therapeutic and Supratherapeutic Concentrations Following a 2-dose EVP-6124 Regimen on the QT Interval in Healthy Male and Female Subjects.

NCT01487135 is registered in ClinicalTrials.gov with FORUM Pharmaceuticals Inc as lead sponsor.

NCT NCT01487135
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01487135 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo- and Active-controlled, 3-way Crossover, Phase 1 Study to Evaluate the Effect of EVP-6124 at Therapeutic and Supratherapeutic Concentrations Following a 2-dose EVP-6124 Regimen on the QT Interval in Healthy Male and Female Subjects.
Lead sponsor
FORUM Pharmaceuticals Inc
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2011
Completion date
September 30, 2013
Enrollment
60 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cardiac repolarization, healthy subjects